Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Policymakers must prioritize access to innovative obesity care in tackling the obesity epidemic across the United States.

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain ...

Medicare Part D coverage of obesity medications could lead to a large increase in health care costs due to the prices of the drugs, according to data from a microsimulation model published in JAMA ...

A decision by CMS to not move forward with a proposed rule allowing obesity medications to be covered under Medicare Part D has several medical societies advocating for change. As Healio ...

The Trump administration’s CMS has declined to expand Medicare coverage for obesity drugs. Credit: Kayla Bartkowski via Getty Images. ·Pharmaceutical Technology·Kayla Bartkowski via Getty Images.

The Biden administration’s rule would have expanded access to obesity drugs, including pricey GLP-1 drugs, to an estimated 3.4 million people on Medicare and 4 million people in Medicaid.

The conversation moves fast. Keep up with the Prompt newsletter. Too bad the Centers for Medicare and Medicaid Services decided on Friday not to broadly cover new anti-obesity medications.

The Biden administration proposal on obesity drugs In November 2024, The Biden administration proposed a rule that would allow both Medicare and Medicaid to cover weight loss drugs beginning in 2026.